Mustang Ventures

Mustang Bio is a clinical-stage biopharmaceutical company focused on developing next-generation cell and gene therapies for hematologic malignancies, solid tumors, and rare genetic diseases. The company's pipeline is built on three core pillars: CAR-T therapies for blood cancers, CAR-T therapies for solid tumors (specifically glioblastoma), and lentiviral gene therapies for X-linked severe combined immunodeficiency (X-SCID). Mustang Bio was founded by Fortress Biotech and maintains strategic partnerships with leading academic institutions such as City of Hope and St. Jude Children's Research Hospital. The company previously operated its own cell therapy manufacturing facility in Massachusetts, which was sold to uBriGene in 2023 to streamline operations while maintaining access to manufacturing capabilities. Their lead programs include MB-106, a CD20-targeted CAR-T therapy, and MB-107, a gene therapy for 'bubble boy' disease.